Tecon Biology Co Ltd
SZSE:002100
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tecon Biology Co Ltd
EPS (Diluted)
Tecon Biology Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tecon Biology Co Ltd
SZSE:002100
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
1%
|
|
|
Tongwei Co Ltd
SSE:600438
|
EPS (Diluted)
-¥1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Heilongjiang Agriculture Co Ltd
SSE:600598
|
EPS (Diluted)
¥0
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
B
|
Beijing Dabeinong Technology Group Co Ltd
SZSE:002385
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-5%
|
|
|
New Hope Liuhe Co Ltd
SZSE:000876
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-9%
|
|
|
Jiangxi Zhengbang Technology Co Ltd
SZSE:002157
|
EPS (Diluted)
¥0
|
CAGR 3-Years
88%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tecon Biology Co Ltd
Glance View
Tecon Biology Co Ltd has carved its niche in the rapidly evolving biotechnology sector, specializing in the development and production of bio-based products and solutions. At its core, the company leverages advanced biological science to create environmentally friendly products that satisfy a range of industrial needs. Operating at the intersection of science and sustainability, Tecon has focused its efforts on the use of microbial fermentation technology and genetic engineering to produce bio-products that support agricultural, pharmaceutical, and environmental applications. By advancing proprietary technological capabilities, the company has demonstrated a commitment to not only commercial success but also environmental stewardship, recognizing the increasing global emphasis on sustainable business practices. The company's financial model is centered around translating cutting-edge biological research into commercially viable products. Tecon Biology generates revenue by licensing its biotechnological innovations to major agricultural and pharmaceutical firms that seek sustainable and cost-effective alternatives to traditional chemical-based products. Additionally, Tecon manufactures and sells its own branded line of bio-products, such as bio-fertilizers and enzyme solutions, directly to end-users both domestically and internationally. This dual approach allows the company to capitalize on the growing demand for sustainable solutions while maintaining diverse revenue streams, thereby enhancing its resilience in the competitive biotech industry. Through strategic collaborations and continuous innovation, Tecon Biology has established itself as a formidable player in the global market, poised to address some of the biggest challenges facing the world today.
See Also
What is Tecon Biology Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.3
CNY
Based on the financial report for Sep 30, 2025, Tecon Biology Co Ltd's EPS (Diluted) amounts to 0.3 CNY.
What is Tecon Biology Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
1%